Black checkmark with a sparkle and a curved line underneath on a white background.
Company

CV Sciences, Inc.

Ticker
CVSI
Sector
Industry
Report date
November 13, 2026
Valye AI Score

93

Very high visibility
Recent developments
Recent developments summary

Recent news coverage includes general market and sector updates with limited direct company-specific developments. Notably, CV Sciences reported a 10% sales decline in August 2025 and announced an acquisition of Extract Labs for growth.

Recent developments:
  • CV Sciences reported a 10 percent decline in sales as of August 2025, indicating challenges in revenue generation [N1].
  • The company announced plans to acquire Extract Labs to support growth initiatives, reflecting strategic expansion efforts [N1].
  • Recent broader market news includes sector-wide movements such as stock declines related to Nvidia and bond yields, which may indirectly affect market sentiment [N1].
Overview

CV Sciences, Inc. develops, manufactures, markets, and sells hemp-derived CBD products and plant-based food products. Its product portfolio includes +PlusCBD™, a top-selling hemp extract brand in the U.S. natural products market, +PlusHLTH™, a cannabinoid-free supplement line, Cultured Foods™, a European plant-based food brand, and Lunar Fox™, a U.S. plant-based food brand. The company distributes products through multiple channels including online platforms, distributors, and brick-and-mortar retailers. It has expanded its manufacturing capabilities through acquisitions such as Elevated Softgels, LLC. CV Sciences operates in a highly regulated environment with evolving federal and state laws impacting hemp-derived products. The company also holds patents related to CBD-based therapeutics but has curtailed development due to capital constraints. Its financial position as of late 2026 shows modest liquidity and a small net loss.

Executive summary

CV Sciences, Inc. is a consumer wellness company specializing in hemp-derived CBD products and plant-based foods, operating primarily in North America and Europe. The company markets products under four brands, including the leading +PlusCBD™ hemp extract brand. It has expanded through acquisitions such as Cultured Foods and Elevated Softgels, and launched new product lines including cannabinoid-free supplements and plant-based foods. The company faces a complex and evolving regulatory environment, with recent federal legislation imposing stricter THC limits effective November 2026, which may impact product sales. Financially, as of September 30, 2026, CV Sciences reported current assets of $4.89 million, current liabilities of $4.15 million, and a net loss of $93,000 for the nine months ended. Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.

Scenarios for CVSI

Bull case model:

CV Sciences benefits from a leading position in the hemp-derived CBD market with a scientifically backed and widely distributed +PlusCBD™ brand. The company's expansion into plant-based foods through acquisitions and new brand launches diversifies its revenue streams. Its flexible manufacturing capabilities and broad distribution network support market reach. Regulatory developments, including potential Medicare coverage for hemp-derived CBD products, could open new market opportunities. The company's ongoing product innovation, with a significant portion of revenue from recent product launches, demonstrates active portfolio management.

Bear case model:

CV Sciences faces significant regulatory uncertainty due to evolving federal and state laws, including stricter THC limits effective November 2026, which may restrict sales of existing hemp-derived products. The company's drug development program is dormant due to capital constraints, limiting diversification into therapeutics. The CBD and plant-based food markets are highly competitive and fragmented, with larger competitors and pricing pressures. Financially, the company reported a net loss and modest liquidity, which may constrain operational flexibility. Dependence on regulatory approvals and potential changes in consumer preferences pose ongoing risks.

Moat:

CV Sciences' moat is anchored in its established +PlusCBD™ brand, recognized as the top-selling hemp extract brand in the U.S. natural products market, supported by scientific research and GRAS status. The company's diversified product portfolio across hemp-derived CBD and plant-based foods, combined with strategic acquisitions, enhances its market presence and manufacturing capabilities. Its ability to serve multiple sales channels, including B2B and B2C, and flexible manufacturing minimum order quantities provide competitive advantages. However, the highly fragmented and competitive nature of the CBD and plant-based food markets, along with evolving regulatory challenges, limit the moat's defensibility.

Risks overview
Risks summary
Regulatory changes imposing stricter THC limits and evolving federal and state laws represent the most significant risk to CV Sciences' business operations and product sales.
Risks details:

• Regulatory Risk: The company operates in a complex and evolving regulatory environment with federal and state laws impacting hemp-derived CBD products. The November 2025 Appropriations Act imposes stricter THC limits effective November 12, 2026, potentially restricting sales of many current products. Changes in FDA policies and state regulations add uncertainty to product marketing and distribution.
• Financial Risk: CV Sciences reported a net loss of $93,000 for the nine months ended September 30, 2026, with modest liquidity ratios (current ratio 1.18, cash ratio 0.15). Limited financial resources may constrain growth initiatives, product development, and regulatory compliance efforts.
• Competitive Risk: The CBD consumer product and European plant-based food markets are highly fragmented and competitive, with numerous public and private companies. Larger competitors with greater resources may challenge CV Sciences' market share and pricing power.
• Operational Risk: The company relies on multiple sales channels and partnerships with distributors and retailers. Disruptions in supply chain, manufacturing, or distribution could impact product availability and sales.

FINAL FORECAST FOR CVSI

Final take one line
CV Sciences operates a diversified hemp-derived CBD and plant-based food business with strong brand recognition and evolving regulatory challenges.
Final take 12 to 24 month view

Business trends: Expansion through acquisitions and new product launches in hemp-derived CBD and plant-based foods amid evolving regulatory frameworks.
Execution milestones: Integration of Cultured Foods and Elevated Softgels acquisitions, launch of Lunar Fox brand, and ongoing product innovation.
Key risks: Regulatory changes imposing stricter THC limits, competitive market pressures, and financial constraints impacting growth and compliance.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

93
LLM visibility overview
LLM Visibility known facts
  • CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods, with a focus on hemp extracts and natural ingredients sold through B2B and B2C channels.
  • The company markets its products under four main brands: +PlusCBD™, +PlusHLTH™, Cultured Foods™, and Lunar Fox™.
  • +PlusCBD™ is the top-selling hemp extract brand in the natural products market in the U.S., supported by human clinical research and GRAS status.
  • +PlusHLTH™ is a cannabinoid-free supplement line launched in 2024, distributed in select U.S. retailers and online.
  • Cultured Foods™ is a European brand offering plant-based, natural, gluten-free, shelf-stable food products, acquired in December 2023.
  • Lunar Fox™ is a U.S. brand launched in March 2025, focused on plant-based, natural, gluten-free, shelf-stable products.
  • The company acquired Elevated Softgels, LLC in May 2024, a manufacturer of encapsulated softgels and tinctures for the supplement industry.
  • CV Sciences has a dormant drug development program for CBD-based therapeutics, including a patented product CVSI-007 combining CBD and nicotine for smokeless tobacco addiction, but further development is curtailed due to capital constraints.
  • The company operates primarily in North America for hemp-based products and Europe for plant-based foods, with sales through online platforms, distributors, and approximately 2,500 brick-and-mortar stores as of 2025.
  • 39% of net revenue for 2025 was from products launched since January 1, 2023, with 39 new products introduced during that period.
  • The company faces a complex regulatory environment with evolving federal and state laws in the U.S., including the 2018 Farm Bill and the November 2025 Appropriations Act which imposes stricter THC limits effective November 12, 2026, potentially impacting product sales.
  • Federal regulatory developments include an Executive Order in December 2025 aimed at rescheduling marijuana and improving access to hemp-derived cannabinoid products, with potential Medicare coverage for hemp-derived CBD products under consideration.
  • CV Sciences monitors regulatory changes continuously and maintains required licenses for sourcing, manufacturing, and distribution.
  • The company’s financial snapshot as of September 30, 2026, shows current assets of $4.89 million, current liabilities of $4.15 million, cash and equivalents of $611,000, a current ratio of 1.18, and a cash ratio of 0.15.
  • Net income for the nine months ended September 30, 2026, was a loss of $93,000 with basic and diluted EPS of $0.00.
  • The company’s business is subject to competitive pressures in the CBD consumer product market and the European plant-based food market, both described as highly fragmented.
  • CV Sciences offers manufacturing capabilities for softgels with flexible minimum order quantities, differentiating from larger competitors requiring larger MOQs.
  • The company’s three largest customers accounted for approximately 8-9% of total sales in recent years, indicating a diversified customer base.
  • Recent news includes a report of CV Sciences sales down 10 percent as of August 2025 and an announcement of the acquisition of Extract Labs for growth, indicating ongoing strategic activity.
Sources
Sources - Context summary

Generated 2026-11-13

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-26 | 10-K
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-11-13 | www.nasdaq.com | Stocks Settle Lower on Nvidia Rout and Higher Crude and Bond Yields | https://www.nasdaq.com/articles/stocks-settle-lower-nvidia-rout-and-higher-crude-and-bond-yields
  • N2 | 2026-11-13 | www.nasdaq.com | Immunic Q3 Loss Widens On Higher Expenses; Phase 3 MS Trial Data Expected In December 2026 | https://www.nasdaq.com/articles/immunic-q3-loss-widens-higher-expenses-phase-3-ms-trial-data-expected-december-2026
  • N3 | 2026-11-13 | www.nasdaq.com | Bluerock Homes Trust, Inc. Disposes of 25 Golden Pacific Units for $6.6 million | https://www.nasdaq.com/articles/bluerock-homes-trust-inc-disposes-25-golden-pacific-units-66-million
  • N4 | 2026-11-13 | www.nasdaq.com | Transcontinental Realty Investors, Inc. Reports Q3 2026 Net Loss of $0.1 million | https://www.nasdaq.com/articles/transcontinental-realty-investors-inc-reports-q3-2026-net-loss-01-million
  • N5 | 2026-11-13 | www.nasdaq.com | Trio-Tech International Reports First Quarter of Fiscal 2027 Revenue of $19.9 million | https://www.nasdaq.com/articles/trio-tech-international-reports-first-quarter-fiscal-2027-revenue-199-million
  • N6 | 2026-11-13 | www.nasdaq.com | This ETF Has Gained 23% This Year. Is It Still Worth Buying in 2026? | https://www.nasdaq.com/articles/etf-has-gained-23-year-it-still-worth-buying-2026
  • N7 | 2026-11-13 | www.nasdaq.com | Teekay Corporation Ltd. Reports Third Quarter 2026 Net Income of $59.8 Million | https://www.nasdaq.com/articles/teekay-corporation-ltd-reports-third-quarter-2026-net-income-598-million
  • N8 | 2026-11-13 | www.nasdaq.com | Stratasys Ltd. Terminates Markforged Acquisition and Reports Q3 2026 Financial Results | https://www.nasdaq.com/articles/stratasys-ltd-terminates-markforged-acquisition-and-reports-q3-2026-financial-results
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine